Natural killer cells in viral infection: More than just killers

Immunological Reviews

Volumn 214, Issue 1, 2006, Pages 239-250

  Andoniou, Christopher E ^a,b   Andrews, Daniel M ^a,b   Degli Esposti, Mariapia A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b LIONS EYE INSTITUTE   (Australia)

Author keywords

Cytomegalovirus; Dendritic cells; Natural killer cells

Indexed keywords

CELLULAR INHIBITOR OF APOPTOSIS PROTEIN; COLONY STIMULATING FACTOR 1; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME A; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADAPTIVE BEHAVIOR; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARENAVIRUS; ATOPIC DERMATITIS; CELL INTERACTION; CELL SURVIVAL; CYTOKINE RELEASE; CYTOMEGALOVIRUS; DENDRITIC CELL; DERMATITIS; DNA DAMAGE; HEPATITIS VIRUS; HERPES VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PARAMYXOVIRUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS INFECTION; VIRUS INTERFERENCE; VIRUS REPLICATION;

ANIMALS; DENDRITIC CELLS; HUMANS; KILLER CELLS, NATURAL; VIRUS DISEASES;

EID: 33750719589     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2006.00465.x     Document Type: Review

References (179)

1. Lian RH, Kumar V. Murine natural killer cell progenitors and their requirements for development. Semin Immunol 2002;14:453-460.
2. Kiessling R, Petranyi G, Klein G, Wigzel H. Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line. Int J Cancer 1975;15:933-940.
3. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985;162:1745-1759.
4. Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
5. Takei F, Brennan J, Mager DL. The Ly-49 family: genes, proteins and recognition of class I MHC. Immunol Rev 1997;155:67-77.
6. Takei F, et al. Ly49 and CD94/NKG2: developmentally regulated expression and evolution. Immunol Rev 2001;181:90-103.
7. Lanier LL. Activating and inhibitory NK cell receptors. Adv Exp Med Biol 1998;452:13-18.
8. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001;1:41-49.
9. Borrego FK, et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 2002;38:637-660.
10. O'Leary JG, Goodarzi M, Drayton DL, von Andrian UH. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol 2006;7:507-516.
11. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005;5:112-124.
12. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
13. Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002;71:173-183.
14. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2:735-747.
15. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365.
16. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 2003;18:1-6.
17. Smyth MJ, Trapani JA Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today 1995;16:202-206.
18. van den Broek MF, Kagi D, Zinkernagel RM, Hengartner H. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol 1995;25:3514-3516.
19. Smyth MJ, et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999;162:6658-6662.
20. Street SE, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 2004;199:879-884.
21. Warfield KL, et al. Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 2004;200:169-179.
22. Tay CH, Welsh RM. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 1997;71:267-275.
23. Loh J, Chu DT, O'Guin AK, Yokoyama WM, Virgin HWt. Natural killer cells utilize both perforin and gamma interferon to regulate murine cytomegalovirus infection in the spleen and liver. J Virol 2005;79:661-667.
24. van Dommelen SLH, Tabarias HA, Smyth MJ, Degli-Esposti MA. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J Virol 2003;77:1877-1884.
25. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003;3:361-370.
26. Smyth MJ, et al. Unlocking the secrets of cytotoxic granule proteins. J Leukoc Biol 2001;70:18-29.
27. Trapani JA Granzymes: a family of lymphocyte granule serine proteases. Genome Biol 2001;2:Reviews3014.
28. Beresford PJ, Xia Z, Greenberg AH, Lieberman J. Granzyme A loading induces rapid cytolysis and a novel form of DNA damage independently of caspase activation. Immunity 1999;10:585-594.
29. Fan Z, et al. Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol 2003;4:145-153.
30. Trapani JA, Sutton VR. Granzyme B.: proapoptotic, antiviral and antitumor functions. Curr Opin Immunol 2003;15:533-543.
31. Mullbacher A, et al. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci USA 1999;96:13950-13995.
32. Regner M, Mullbacher A. Granzymes in cytolytic lymphocytes to kill a killer? Immunol Cell Biol 2004;82:161-169.
33. Smyth MJ, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)g contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-670.
34. Takeda K, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100.
35. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356-1361.
36. Sato K, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001;31:3138-3146.
37. Kemp TJ, Elzey BD, Griffith TS. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003;171:212-218.
38. Screpanti V, Wallin RP, Ljunggren HG, Grandien A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol 2001;167:2068-2073.
39. Yokoyama WM, Daniels BF, Seaman WE, Hunziker R, Margulies DH, Smith HR. A family of murine NK cell receptors specific for target cell MHC class I molecules. Semin Immunol 1995;7:89-101.
40. Yokoyama WM. Natural killer cell receptors. Curr Opin Immunol 1995;7:110-120.
41. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991;173:1017-1020.
42. Diefenbach A, et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002;3:1142-1149.
43. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8 alpha beta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001;2:255-260.
44. Welte SA, et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 2003;33:194-203.
45. Lodoen M, et al. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 2003;197:1245-1253.
46. Eagle RA, Traherne JA, Ashiru O, Wills MR, Trowsdale J. Regulation of NKG2D ligand gene expression. Hum Immunol 2006;67:159-169.
47. Cosman D, et al. ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133.
48. Krmpotic A, et al. MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol 2002;3:529-535.
49. Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, Spies T. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol 2003;170:4196-4200.
50. Dunn C, et al. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med 2003;197:1427-1439.
51. Lodoen MB, Abenes G, Umamoto S, Houchins JP, Liu F, Lanier LL. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med 2004;200:1075-1081.
52. Krmpotic A, et al. NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med 2005;201:211-220.
53. Hasan M, et al. Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J Virol 2005;79:2920-2930.
54. Lenac T, et al. The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med 2006;203:1843-1850.
55. Chalupny NJ, Rein-Weston A, Dosch S, Cosman D. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 2006;346:175-181.
56. Smith HR, et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci USA 2002;99:8826-8831.
57. Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 1996;5:311-317.
58. Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 1988;141:3478-3485.
59. Granucci F, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med 2004;200:287-295.
60. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-1531.
61. Jinushi M, et al. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 2003;171:5423-5429.
62. Dalod M, et al. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J Exp Med 2003;197:885-898.
63. Zinkernagel RM, Doherty PC. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 1974;251:547-548.
64. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974;248:701-702.
65. Kiessling R, Klein E, Pross H, Wigzell H. ''Natural'' killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975;5:117-121.
66. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975;5:112-117.
67. Kiessling R, Petranyi G, Karre K, Jondal M, Tracey D, Wigzell H. Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. J Exp Med 1976;143:772-780.
68. Kiessling R, Petranyi G, Klein G, Wigzell H. Non-T-cell resistance against a mouse Moloney lymphoma. Int J Cancer 1976;17:275-281.
69. Santoli D, Trinchieri G, Koprowski H. Cell-mediated cytotoxicity against virus-infected target cells in humans. II. Interferon induction and activation of natural killer cells. J Immunol 1978;121:532-538.
70. Santoli D, Trinchieri G, Lief FS. Cell-mediated cytotoxicity against virus-infected target cells in humans. I. Characterization of the effector lymphocyte. J Immunol 1978;121:526-531.
71. Trinchieri G, Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978;147:1314-1333.
72. Trinchieri G, Santoli D, Dee RR, Knowles BB. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the antiviral activity as interferon and characterization of the human effector lymphocyte subpopulation. J Exp Med 1978;147:1299-1313.
73. Welsh RM Jr. Mouse natural killer cells: induction specificity, and function. J Immunol 1978;121:1631-1635.
74. Welsh RM Jr. Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice. I. Characterization of natural killer cell induction. J Exp Med 1978;148:163-181.
75. Welsh RM Jr., Kiessling RW. Natural killer cell response to lymphocytic choriomeningitis virus in beige mice. Scand J Immunol 1980;11:363-367.
76. Welsh RM Jr., Zinkernagel RM, Hallenbeck LA. Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice. II. ''Specificities'' of the natural killer cells. J Immunol 1979;122:475-481.
77. Doyle LB, Doyle MV, Oldstone MB. Susceptibility of newborn mice with H-2k backgrounds to lymphocytic choriomeningitis virus infection. Immunology 1980;40:589-596.
78. Anderson MJ. Innate cytotoxicity of CBA mouse spleen cells to Sendai virus-infected L cells. Infect Immun 1978;20:608-612.
79. Anderson MJ, Bainbridge DR, Pattison JR, Heath RB. Cell-mediated immunity to Sendai virus infection in mice. Infect Immun 1977;15:239-244.
80. Macfarlan RI, Ceredig R, White DO. Comparison of natural killer cells induced by Kunjin virus and Corynebacterium parvum with those occurring naturally in nude mice. Infect Immun 1979;26:832-836.
81. Macfarlan RI, White DO. Further characterization of natural killer cells induced by Kunjin virus. Aust J Exp Biol Med Sci 1980;58:77-89.
82. Koziel MJ. NK cells: natural born killers in the conflict between humans and HCV. Hepatology 2006;43:395-397.
83. Li Y, Zhang T, Ho C, Orange JS, Douglas SD, Ho WZ. Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol 2004;76:1171-1179.
84. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol 2005;5:835-843.
85. Shresta S, Kyle JL, Robert Beatty P, Harris E. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology 2004;319:262-273.
86. Quaresma JA, et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology 2006;345:22-30.
87. Crotta S, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002;195:35-41.
88. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002;195:43-49.
89. Meier UC, et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol 2005;79:12365-12374.
90. Jinushi M, et al. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 2003;170:1249-1256.
91. Quinnan GV, Manischewitz JE, Ennis FA. Cytotoxic T lymphocyte response to murine cytomegalovirus infection. Nature 1978;273:541-543.
92. Chalmer JE, Mackenzie JS, Stanley NF. Resistance to murine cytomegalovirus linked to the major histocompatibility complex of the mouse. J Gen Virol 1977;37:107-114.
93. Selgrade MK, Osborn JE. Role of macrophages in resistance to murine cytomegalovirus. Infect Immun 1974;10:1383-1390.
94. Bancroft GJ, Shellam GR, Chalmer JE. Genetic influences on the augmentation of natural killer (NK) cells during murine cytomegalovirus infection: correlation with patterns of resistance. J Immunol 1981;126:988-994.
95. Scalzo AA, et al. The effect of the Cmv1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J Immunol 1992;149:581-589.
96. Brown MG, et al. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 2001;292:934-937.
97. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002;296:1323-1326.
98. Daniels KA, Devora G, Lai WC, O'Donnell CL, Bennett M, Welsh RM. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J Exp Med 2001;194:29-44.
99. Rawlinson WD, Farrell HE, Barrell BG. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol 1996;70:8833-8849.
100. Osborn JE, Blazkovec AA, Walker DL. Immunosuppression during acute murine cytomegalovirus infection. J Immunol 1968;100:835-844.
101. Osborn JE, Medearis DN Jr. Suppression of interferon and antibody and multiplication of Newcastle disease virus in cytomegalovirus infected mice. Proc Soc Exp Biol Med 1967;124:347-353.
102. Howard RJ, Najarian JS Cytomegalovirus-induced immune suppression. I. Humoral immunity. Clin Exp Immunol 1974;18:109-113.
103. Howard RJ, Miller J, Najarian JS. Cytomegalovirus-induced immune suppression. II. Cell-mediated immunity. Clin Exp Immunol 1974;18:119-126.
104. Gehrz RC, Marker SC, Balfour HH Jr. Specific cell-mediated immune defect in congenital cytomegalovirus infection. Lancet 1977;1:811-812.
105. Gehrz RC, Marker SC, Knorr SO, Kalis JM, Balfour HH Jr. Specific cell-mediated immune defect in active cytomegalovirus infection of young children and their mothers. Lancet 1977;2:844-847.
106. Booss J, Wheelock EF. Progressive inhibition of T-cell function preceding clinical signs of cytomegalovirus infection in mice. J Infect Dis 1977;135:478-481.
107. Schrier RD, Oldstone MB. Recent clinical isolates of cytomegalovirus suppress human cytomegalovirus-specific human leukocyte antigen-restricted cytotoxic T-lymphocyte activity. J Virol 1986;59:127-131.
108. Fujinami RS, Nelson JA, Walker L, Oldstone MB. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. J Virol 1988;62:100-105.
109. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 1988;331:269-272.
110. Schrier RD, Rice GP, Oldstone MB. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis 1986;153:1084-1091.
111. Farrell HE, et al. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 1997;386:510-514.
112. Reyburn HT, Mandelboim O, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997;386:514-517.
113. del Val M, et al. Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J Exp Med 1992;176:729-738.
114. Del Val M, Munch K, Reddehase MJ, Koszinowski UH. Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase. Cell 1989;58:305-315.
115. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-678.
116. Cerwenka A, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000;12:721-727.
117. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000;1:119-126.
118. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 2002;169:4079-4083.
119. Zou Y, Bresnahan W, Taylor RT, Stastny P. Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol 2005;174:3098-3104.
120. Zhang Y, Lazaro AM, Lavingia B, Stastny P. Typing for all known MICA alleles by group-specific PCR and SSOP. Hum Immunol 2001;62:620-631.
121. Arnon TI, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005;6:515-523.
122. Andrews DM, Andoniou CE, Granucci F, Ricciardi-Castagnoli P, Degli-Esposti MA. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nat Immunol 2001;2:1077-1084.
123. Riegler S, Hebart H, Einsele H, Brossart P, Jahn G, Sinzger C. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol 2000;81:393-399.
124. Riegler S, Hebart H, Einsele H, Grigoleit U, Jahn G, Sinzger C. Dendritic cells infected by endothelial cell propagated strains of HCMV are functionally altered. In: Johnson DC, Nelson JA, eds. 25th International Herpesvirus Workshop, Portland, Oregon, 2000.
125. Soderberg-Naucler C, Fish KN, Nelson JA. Growth of human cytomegalovirus in primary macrophages. Methods 1998;16:126-138.
126. Soderberg-Naucler C, Streblow DN, Fish KN, Allan-Yorke J, Smith PP, Nelson JA. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol 2001;75:7543-7554.
127. Schrier RD, Nelson JA, Oldstone MB. Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science 1985;230:1048-1051.
128. Rice GP, Schrier RD, Oldstone MB. Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci USA 1984;81:6134-6138.
129. Andoniou CE, et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 2005;6:1011-1019.
130. Rodriguez M, Sabastian P, Clark P, Brown MG. Cmv1-independent antiviral role of NK cells revealed in murine cytomegalovirus-infected New Zealand White mice. J Immunol 2004;173:6312-6318.
131. Desrosiers MP, et al. Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat Genet 2005;37:593-599.
132. Steinman RM. Some interfaces of dendritic cell biology. APMIS 2003;111:675-697.
133. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-995.
134. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2:151-161.
135. Heath WR, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004;199:9-26.
136. Boonstra A, et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 2003;197:101-109.
137. Fernandez NC, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-411.
138. Yu Y, et al. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol 2001;166:1590-1600.
139. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-333.
140. Ferlazzo G, et al. The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol 2003;33:306-313.
141. Asselin-Paturel C, Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 2005;202:461-465.
142. Lopez CB, Garcia-Sastre A, Williams BR, Moran TM. Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis 2003;187:1126-1136.
143. Diebold SS, et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003;424:324-328.
144. Ferlazzo G, et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA 2004;101:16606-16611.
145. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002;195:335-341.
146. Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol 2003;4:801-807.
147. Wilson JL, Heffler LC, Charo J, Scheynius A, Bejarano MT, Ljunggren HG. Targeting of human dendritic cells by autologous NK cells. J Immunol 1999;163:6365-6370.
148. Carbone E, et al. Recognition of autologous dendritic cells by human NK cells. Eur J Immunol 1999;29:4022-4029.
149. Della Chiesa M, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol 2003;33:1657-1666.
150. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343-351.
151. Hayakawa Y, et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 2004;172:123-129.
152. Kayagaki N, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 1999;163:1906-1913.
153. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol 2004;172:1333-1339.
154. Bjork P, Banchereau J, Flores-Romo L. CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. Int Immunol 1997;9:365-372.
155. Pirtskhalaishvili G, et al. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer 2000;84:506-513.
156. Park Y, Lee SW, Sung YC. CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3#-OH kinase pathway. J Immunol 2002;168:5-8.
157. Willems F, et al. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood 2000;95:3478-3482.
158. Hasebe H, et al. Bcl-2, Bcl-xL and c-FLIP(L) potentially regulate the susceptibility of human peripheral blood monocyte-derived dendritic cells to cell death at different developmental stages. Biomed Pharmacother 2002;56:144-151.
159. Ricci MS, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004;24:8541-8555.
160. Vitale M, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005;106:566-571.
161. Buentke E, et al. Natural killer and dendritic cell contact in lesional atopic dermatitis skin - Malassezia-influenced cell interaction. J Invest Dermatol 2002;119:850-857.
162. Buentke E, D'Amato M, Scheynius A. Malassezia enhances natural killer cell-induced dendritic cell maturation. Scand J Immunol 2004;59:511-516.
163. Borg C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004;114:379-388.
164. Ferlazzo G, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004;172:1455-1462.
165. Kim CH, Pelus LM, Appelbaum E, Johanson K, Anzai N, Broxmeyer HE. CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors. Cell Immunol 1999;193:226-235.
166. Bajenoff M, et al. Natural killer cell behavior in lymph nodes revealed by static and real-time imaging. J Exp Med 2006;203:619-631.
167. Cooper MA, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-3151.
168. Martin-Fontecha A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004;5:1260-1265.
169. Asselin-Paturel C, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001;2:1144-1150.
170. Dalod M, et al. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta [erratum appears in J Exp Med 2003;197:following 1227]. J Exp Med 2003;197:885-898.
171. Krug A, et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004;21:107-119.
172. Delale T, et al. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol 2005;175:6723-6732.
173. Andrews DM, et al. Cross-talk between dendritic cells and natural killer cells in viral infection. Mol Immunol 2005;42:547-555.
174. Josien R, Heslan M, Soulillou JP, Cuturi MC. Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism. J Exp Med 1997;186:467-472.
175. Hanna J, et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest 2004;114:1612-1623.
176. Pillarisetty VG, Katz SC, Bleier JI, Shah AB, Dematteo RP. Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. J Immunol 2005;174:2612-2618.
177. Chan CW, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006;12:207-213.
178. Taieb J, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006;12:214-219.
179. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.